SML0552
替拉扎明
≥98% (HPLC), Pro-apoptotic, powder
别名:
4-羟基-1-氧-1,2,4-苯并三嗪-1-鎓-3-亚胺, SR 259075, SR 4233, Win 59075, 三嗪酮
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C7H6N4O2
化学文摘社编号:
分子量:
178.15
UNSPSC Code:
12352116
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
替拉扎明, ≥98% (HPLC)
SMILES string
Nc1n[n+]([O-])c2ccccc2[n+]1[O-]
InChI
1S/C7H6N4O2/c8-7-9-11(13)6-4-2-1-3-5(6)10(7)12/h1-4H,(H2,8,9)
InChI key
ORYDPOVDJJZGHQ-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
, orange to dark orange-red
solubility
DMSO: 10 mg/mL, clear
shipped in
wet ice
storage temp.
−20°C
Quality Level
相关类别
Application
已经使用替拉扎明评估其对U-251 MG（成胶质细胞瘤细胞系）细胞活力的细胞毒性作用。
Biochem/physiol Actions
在低氧条件下，替拉扎明是一种有效的细胞毒性剂，通过诱导单链和双链DNA的断裂以及染色体断裂诱导细胞凋亡。 该化合物可使细胞对其他电离辐射和其他细胞毒性药物（如顺铂）敏感。
在缺氧条件下，替拉扎明是有效的细胞毒性药物。
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
A V Patterson et al.
Anti-cancer drug design, 13(6), 541-573 (1998-10-02)
The enzymology of triapazamine (TPZ, SR 4233, WIN 59075, 3-amino-1,2,4-benzotriazene 1,4-dioxide, Tirazone) has been extensively studied in rodents and to a lesser extent in human systems. While it is clear that the initial reductive step in TPZ activation is enzyme-mediated
Prafull Ghatage et al.
Expert opinion on drug metabolism & toxicology, 8(12), 1589-1597 (2012-10-05)
Cervical cancer is the second-most common malignancy in women worldwide. Cisplatin was introduced as a radiosensitizer in 1999 to improve chances of survival. Tumor cell hypoxia, however, remains a major limiting factor in the treatment of solid tumors with chemotherapy
Klaas M Govaert et al.
Annals of surgery, 259(4), 750-759 (2013-11-21)
To assess the contribution of hypoxia and bone marrow-derived cells to aggressive outgrowth of micrometastases after liver surgery. Liver surgery generates a microenvironment that fosters aggressive tumor recurrence. These areas are characterized by chronic hypoxia and influx of bone marrow-derived
J M Brown
British journal of cancer, 67(6), 1163-1170 (1993-06-01)
SR 4233 (3-amino-1,2,4-benzotriazine 1,4-dioxide, WIN 59075, tirapazamine) is the lead compound in a new class of bioreductive anticancer drugs, the benzotriazine di-N-oxides. It is currently undergoing Phase I clinical testing. The preferential tumour cell killing of SR 4233 is a
W A Denny et al.
Expert opinion on investigational drugs, 9(12), 2889-2901 (2000-11-28)
Tirapazamine is the second clinical anticancer drug (after porfiromycin) that functions primarily as a hypoxia-selective cytotoxin. Hypoxic cells in tumours are relatively resistant to radiotherapy and to some forms of chemotherapy and are also biologically aggressive, thus representing an important
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持